Home / Business / J & J awarded $ 8 billion in antipsychotic drugs

J & J awarded $ 8 billion in antipsychotic drugs

A Philadelphia jury has ordered on Tuesday

Johnson & Johnson

JNJ -0.99%

to a man in Maryland who said that taking J & J's antipsychotic Risperdal as a child led to breast augmentation to pay $ 8 billion in compensation More than 13,000 lawsuits against J & J alleging that Risperdal has caused a condition called gynecomastia in boys, which involves enlargement of breast tissue. The complaints generally claim that J & J was aware of the risk of this side effect, but underestimated the risk to physicians.

This is also the latest in a series of costly legal setbacks for J & J in a series of lawsuits in which infringements due to products and medicines are claimed to be other claims. In August, a judge in Oklahoma called on the company to pay $ 572 million to contribute to the state's opioid addiction crisis.

Last year, a jury in St. Louis found that J & J should pay $ 4.69 billion in damages to women and their families who blamed ovarian cancers for using the company's baby powder ,

J & J has denied the allegations and tried to appeal the decisions on baby powder and opioids. Last week, J & J said it had agreed to pay $ 20.4 million to settle lawsuits filed by two Ohio counties as it contributed to the triggers of the opioid epidemic. The company gave no liability.

In appeal decisions, judges often reduce jury punitive damages sums.

The most recent judgment comes from a lawsuit by

Nicholas Murray,

Who said that his use of Risperdal between 2003 and 2008 caused gynecomastia. In 201

5, a jury in Philadelphia awarded Mr. Murray $ 1.75 million in damages, which a judge reduced to $ 680,000. However, at that time, the judge had prohibited the jury from awarding punitive damages. J & J, headquartered in New Brunswick, New Brunswick, New Jersey, USA, said in a statement on Tuesday that the phase of punitive damages proceedings will begin in September and end with the ruling From Tuesday to end excessive and unfounded judgment. The company said the amount was "grossly disproportionate" to the initial $ 680,000 compensation payment and it is confident that the verdict will be lifted. Exclusion of important evidence by the court and correct presentation of risks on the prescription label for Risperdal.

Mr. Murray's attorneys Thomas Kline and

Jason Itkin,

In a statement, the jury said that "Johnson & Johnson has been strongly asserted that his actions were deliberate and malicious" US patent exclusivity in 2008.

Please call Peter Loftus at peter.loftus @ wsj.com

Copyright © 2019 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Source link